Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Nov;55(11):695-703.
doi: 10.1358/dot.2019.55.11.3069864.

Eptinezumab for the treatment of migraine

D Scuteri  1 , M T Corasaniti  2 , P Tonin  3 , G Bagetta  4
Affiliations
Review

Eptinezumab for the treatment of migraine

D Scuteri et al. Drugs Today (Barc). 2019 Nov.

Abstract

Eptinezumab (ALD-403) is a genetically engineered humanized IgG1kappa directed towards calcitonin gene-related peptide (CGRP), currently in late-stage clinical development. Eptinezumab targets the pathway of CGRP, importantly implicated in migraine pathophysiology, and may represent the first-to-market infusion therapy for migraine prevention. The background for its approval consists in preclinical data and clinical trials. Here, we provide a comprehensive review of molecular pharmacology, pharmacokinetics, metabolism, efficacy and safety investigated in the preclinical and clinical studies, with insight on possible future directions.

Keywords: ALD-403; Analgesic drugs; Anti-calcitonin gene-related peptide (CGRP) treatments; Eptinezumab; Migraine; Monoclonal antibodies.

PubMed Disclaimer

MeSH terms

Substances